Posted by me on 12/12/09 on www.hotcopper.com.au
'"IMO,, re: takeover, This will only occur AFTER, at the earliest, at the completion of PhIIb trials..... and this is only bcoz the data will provide much more information than the previous trials. For instance, the PhIIa trail, I think there was a 19% very good response rate to CVAC..... and they only used like 28 people. ALL OF WHO were patients in dire circumstances! To put it into perspective tho, I think Dendreon's Provenge had a similar 19% improvement rate in their same trial, from memory (please don't quote me on that one)..... AND PRR were using patients who's cancer was incredibly progressed!
However, my point is, This PhIIb trial will be used on a range of patients and not merely on patients who's ovarian cancer has progressed too far (From my understanding)
So I mean, our PhIIa trial data was like 19% improvements in VERY PROGRESSED cancer patients..... NOW the current PhIIb trial data is going to obviously be much better than 19% bcoz we are dealing with healthier patients.. so that's going to be interesting, not only from an investor point of view but also from that of social viewpoint. I love women and I want ovarian cancer to be defeated (Preferably by PRR).."
No comments:
Post a Comment